HK1169110A1 - Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt phosphorylation inhibitors (6--16--2-) akt - Google Patents
Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt phosphorylation inhibitors (6--16--2-) aktInfo
- Publication number
- HK1169110A1 HK1169110A1 HK12109790.9A HK12109790A HK1169110A1 HK 1169110 A1 HK1169110 A1 HK 1169110A1 HK 12109790 A HK12109790 A HK 12109790A HK 1169110 A1 HK1169110 A1 HK 1169110A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- akt
- pyrimidin
- dihydro
- oxo
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0903239A FR2947547B1 (fr) | 2009-07-02 | 2009-07-02 | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
US24110009P | 2009-09-10 | 2009-09-10 | |
FR0957070A FR2951169B1 (fr) | 2009-10-09 | 2009-10-09 | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
PCT/FR2010/051375 WO2011001114A1 (fr) | 2009-07-02 | 2010-07-01 | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1169110A1 true HK1169110A1 (en) | 2013-01-18 |
Family
ID=42635553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12109790.9A HK1169110A1 (en) | 2009-07-02 | 2012-10-05 | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt phosphorylation inhibitors (6--16--2-) akt |
Country Status (37)
Country | Link |
---|---|
US (2) | US8791255B2 (ru) |
EP (1) | EP2448927B1 (ru) |
JP (1) | JP5680638B2 (ru) |
KR (1) | KR20120106714A (ru) |
CN (1) | CN102548970B (ru) |
AR (1) | AR077364A1 (ru) |
AU (1) | AU2010267816B2 (ru) |
CA (1) | CA2767064C (ru) |
CL (1) | CL2012000003A1 (ru) |
CO (1) | CO6480974A2 (ru) |
CR (1) | CR20110703A (ru) |
DK (1) | DK2448927T3 (ru) |
DO (1) | DOP2011000407A (ru) |
EA (1) | EA021088B1 (ru) |
EC (1) | ECSP12011570A (ru) |
ES (1) | ES2464125T3 (ru) |
HK (1) | HK1169110A1 (ru) |
HN (1) | HN2011003482A (ru) |
HR (1) | HRP20140478T1 (ru) |
IL (2) | IL217295A (ru) |
MA (1) | MA33501B1 (ru) |
ME (1) | ME01885B (ru) |
MX (1) | MX2012000094A (ru) |
MY (1) | MY153042A (ru) |
NI (1) | NI201200002A (ru) |
NZ (1) | NZ597579A (ru) |
PE (1) | PE20120640A1 (ru) |
PL (1) | PL2448927T3 (ru) |
PT (1) | PT2448927E (ru) |
RS (1) | RS53317B (ru) |
SG (2) | SG10201402867TA (ru) |
SI (1) | SI2448927T1 (ru) |
SM (1) | SMT201400084B (ru) |
TW (1) | TWI466883B (ru) |
UY (1) | UY32755A (ru) |
WO (1) | WO2011001114A1 (ru) |
ZA (1) | ZA201200026B (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2969609B1 (fr) * | 2010-12-28 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 6-oxo-dihydro-pyrimidine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
FR2969614A1 (fr) * | 2010-12-28 | 2012-06-29 | Sanofi Aventis | Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
LT2658844T (lt) | 2010-12-28 | 2017-02-10 | Sanofi | Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių |
FR2969610B1 (fr) * | 2010-12-28 | 2013-04-05 | Sanofi Aventis | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
CA2826387A1 (en) * | 2011-02-11 | 2012-08-16 | Dana Farber Cancer Institute, Inc. | Method of inhibiting hamartoma tumor cells |
EP2570127A1 (en) | 2011-09-16 | 2013-03-20 | Sanofi | Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors |
CA2904770A1 (en) | 2013-03-15 | 2014-09-18 | Sanofi | Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance |
CA2908640A1 (en) | 2013-04-05 | 2014-10-09 | Sanofi | Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor |
CA2966224C (en) | 2014-12-02 | 2019-05-07 | Halliburton Energy Services, Inc. | Liquefied natural gas vaporizer for downhole oil or gas applications |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
JP2003511378A (ja) | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
EP1857443B1 (en) | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
US7365069B2 (en) * | 2002-04-10 | 2008-04-29 | Bexel Pharmaceuticals Inc. | Pyrimidone derivatives |
CA2495661C (en) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
ES2285517T3 (es) * | 2003-10-31 | 2007-11-16 | Warner-Lambert Company Llc | Pirimidinas como inhibidores de fosfoinositida-3-cinasas(pi3k). |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
WO2006126010A2 (en) | 2005-05-26 | 2006-11-30 | Kudos Pharmaceuticals Limited | Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies |
US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
WO2008148074A2 (en) | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibitors of mtor and methods of treatment using same |
AR067478A1 (es) | 2007-07-09 | 2009-10-14 | Astrazeneca Ab | Compuestos derivados de morfolina pirimidina |
US20100261723A1 (en) * | 2007-07-09 | 2010-10-14 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
EA018708B1 (ru) | 2007-07-09 | 2013-10-30 | Астразенека Аб | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K |
CN101801963A (zh) | 2007-07-09 | 2010-08-11 | 阿斯利康(瑞典)有限公司 | 用于治疗增殖性疾病的三取代的嘧啶衍生物 |
AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
-
2010
- 2010-07-01 RS RS20140306A patent/RS53317B/en unknown
- 2010-07-01 AR ARP100102350A patent/AR077364A1/es unknown
- 2010-07-01 PL PL10742014T patent/PL2448927T3/pl unknown
- 2010-07-01 PE PE2012000004A patent/PE20120640A1/es not_active Application Discontinuation
- 2010-07-01 WO PCT/FR2010/051375 patent/WO2011001114A1/fr active Application Filing
- 2010-07-01 EP EP10742014.3A patent/EP2448927B1/fr active Active
- 2010-07-01 SG SG10201402867TA patent/SG10201402867TA/en unknown
- 2010-07-01 AU AU2010267816A patent/AU2010267816B2/en not_active Ceased
- 2010-07-01 DK DK10742014.3T patent/DK2448927T3/da active
- 2010-07-01 NZ NZ597579A patent/NZ597579A/xx not_active IP Right Cessation
- 2010-07-01 ES ES10742014.3T patent/ES2464125T3/es active Active
- 2010-07-01 PT PT107420143T patent/PT2448927E/pt unknown
- 2010-07-01 JP JP2012518120A patent/JP5680638B2/ja not_active Expired - Fee Related
- 2010-07-01 MY MYPI2011006377 patent/MY153042A/en unknown
- 2010-07-01 EA EA201270111A patent/EA021088B1/ru not_active IP Right Cessation
- 2010-07-01 SI SI201030607T patent/SI2448927T1/sl unknown
- 2010-07-01 CN CN201080039214.XA patent/CN102548970B/zh not_active Expired - Fee Related
- 2010-07-01 ME MEP-2014-62A patent/ME01885B/me unknown
- 2010-07-01 CA CA2767064A patent/CA2767064C/fr not_active Expired - Fee Related
- 2010-07-01 MA MA34593A patent/MA33501B1/fr unknown
- 2010-07-01 MX MX2012000094A patent/MX2012000094A/es active IP Right Grant
- 2010-07-01 KR KR1020127002839A patent/KR20120106714A/ko active IP Right Grant
- 2010-07-01 SG SG2011097938A patent/SG177469A1/en unknown
- 2010-07-02 UY UY0001032755A patent/UY32755A/es not_active Application Discontinuation
- 2010-07-02 TW TW99121906A patent/TWI466883B/zh not_active IP Right Cessation
-
2011
- 2011-12-21 CR CR20110703A patent/CR20110703A/es unknown
- 2011-12-26 DO DO2011000407A patent/DOP2011000407A/es unknown
- 2011-12-27 US US13/338,011 patent/US8791255B2/en not_active Expired - Fee Related
- 2011-12-29 IL IL217295A patent/IL217295A/en not_active IP Right Cessation
- 2011-12-29 CO CO11180700A patent/CO6480974A2/es active IP Right Grant
- 2011-12-30 HN HN2011003482A patent/HN2011003482A/es unknown
-
2012
- 2012-01-01 IL IL217321A patent/IL217321A0/en unknown
- 2012-01-02 CL CL2012000003A patent/CL2012000003A1/es unknown
- 2012-01-03 ZA ZA2012/00026A patent/ZA201200026B/en unknown
- 2012-01-03 EC EC2012011570A patent/ECSP12011570A/es unknown
- 2012-01-05 NI NI201200002A patent/NI201200002A/es unknown
- 2012-10-05 HK HK12109790.9A patent/HK1169110A1/xx not_active IP Right Cessation
-
2014
- 2014-05-28 HR HRP20140478AT patent/HRP20140478T1/hr unknown
- 2014-06-23 US US14/312,124 patent/US8993565B2/en not_active Expired - Fee Related
- 2014-06-26 SM SM201400084T patent/SMT201400084B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1164050A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
IL214175A (en) | Derivatives of aminotetralin, their pharmaceutical compositions and their use | |
IL220863A (en) | Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses | |
HK1169110A1 (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt phosphorylation inhibitors (6--16--2-) akt | |
HK1162352A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
ZA201206223B (en) | Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof | |
ZA201202906B (en) | Novel naphthyridine derivatives and the use thereof as kinase inhibitors | |
IL225626A0 (en) | The history of pyrrolidinone, their preparation and remote preparations containing them | |
IL211018A (en) | Inhibitors, processes for making them, medicinal preparations containing them and their use | |
IL206394A (en) | Derivatives of 2-Benzylpyridine Filtration as Met Kinase Inhibitors, Process for their Preparation, Medication and Use | |
HK1161878A1 (en) | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | |
IL215497A0 (en) | Oxadiazile derivatives and pharmaceutical compositions containing them | |
PT2658844T (pt) | Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb) | |
IL209840A0 (en) | Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors | |
IL211713A (en) | History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs | |
ME01491B (me) | Novi derivati dihidroindolona, postupak za njihovu pripremu i farmaceutski spojevi koji ih sadržavaju | |
EP2386553A4 (en) | BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
PT2504331E (pt) | Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização | |
IL214408A0 (en) | Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors | |
EP2424533A4 (en) | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS | |
EP2320738A4 (en) | SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF | |
ZA201203531B (en) | Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof | |
EP2452681A4 (en) | SALTS OF 13A- (S-) DESOXYTYLPHORININE, METHOD FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | |
ZA201204339B (en) | Novel (heterocycle-tetrahydropyridine)(piperazinyl)-1-alcanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alcanone derivatives,and use thereof as p75 inhibitors | |
IL217351A (en) | Derivatives 2 - Amino - Phenyl - Alkanol, Preparation and Pharmaceutical Preparations Containing Them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180701 |